LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

LLY

1,072.27

+1.4%↑

JNJ

206

-1.09%↓

ABBV

227.14

+1.9%↑

UNH

327.43

-0.31%↓

AZN

91.35

+0.79%↑

Inicio・Lista de Acciones・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Cerrado

SectorSalud

20.62 2.33

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

20.51

Máximo

21.14

Métricas clave
By Trading Economics
Ingresos	11M -61M
Ventas	7.9M 46M
BPA	-0.7
Margen de beneficio	-132.36
Empleados	270
EBITDA	6.3M -58M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 meses	+85.36% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	685M 1.8B
Apertura anterior	18.29
Cierre anterior	20.62

Noticias sobre sentimiento de mercado

By Acuity

80%

20%

348 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

9.91 / 14.15 Soporte y Resistencia

Syndax Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

19 dic 2025, 17:29 UTC

Adquisiciones, fusiones, absorciones

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- 2nd Update

19 dic 2025, 16:47 UTC

Principales Movimientos del Mercado

Galectin Shares Fall After FDA Raises Issues With Belapectin Program

19 dic 2025, 16:10 UTC

Adquisiciones, fusiones, absorciones

Union Pacific, Norfolk Southern File for Merger Approval From Surface Transportation Board -- Update

20 dic 2025, 19:00 UTC

Ganancias

Consumer Confidence, Economic Activity Data, and a Short Trading Week for Christmas -- Barrons.com

19 dic 2025, 22:33 UTC

Ganancias

Volkswagen Halts Imports of Its Electric Bus to U.S. Next Year -- WSJ

19 dic 2025, 22:19 UTC

Ganancias

FedEx Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

19 dic 2025, 21:48 UTC

Adquisiciones, fusiones, absorciones

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dic 2025, 21:44 UTC

Ganancias

These Stocks Moved the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 dic 2025, 21:38 UTC

Ganancias

Get Ready for New Chip Shortages. Micron's Success All But Guarantees It. -- Barrons.com

19 dic 2025, 21:00 UTC

Charlas de Mercado

BEA's Trade-Data Catchup Will Continue Into January -- Market Talk

19 dic 2025, 20:23 UTC

Charlas de Mercado

Oil Futures End Down Week on Up Note -- Market Talk

19 dic 2025, 20:14 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Daily Gain, Weekly Loss -- Market Talk

19 dic 2025, 18:38 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls By 8 to 406 -- Market Talk

19 dic 2025, 18:00 UTC

Charlas de Mercado

Ganancias

Nike's Margin Outlook Shows Quarter-to-Quarter Improvement -- Market Talk

19 dic 2025, 17:41 UTC

Ganancias

These Stocks Are Moving the Most Today: Oracle, Nike, Micron, DJT, Carnival, BioMarin, CoreWeave, Lamb Weston, and More -- Barrons.com

19 dic 2025, 17:24 UTC

Charlas de Mercado

Ganancias

Nike's North America Business is Bright Spot in Turnaround -- Market Talk

19 dic 2025, 17:20 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Tech, Media & Telecom Roundup: Market Talk

19 dic 2025, 17:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

19 dic 2025, 16:29 UTC

Ganancias

These Stocks Are Moving the Most Today: Oracle, Nike, FedEx, Micron, DJT, Carnival, BioMarin, Lamb Weston, Winnebago, and More -- Barrons.com

19 dic 2025, 16:20 UTC

Adquisiciones, fusiones, absorciones

CPKC: Anticipates Submitting Comments to Surface Transportation Board in Accordance With Procedural Schedule

19 dic 2025, 16:19 UTC

Adquisiciones, fusiones, absorciones

CPKC: Approval of Union Pacific-Norfolk Southern Merger Isn't Inevitable

19 dic 2025, 16:18 UTC

Adquisiciones, fusiones, absorciones

CPKC: Will Be Thoroughly Reviewing Union Pacific-Norfolk Southern Merger Application Over Coming Days

19 dic 2025, 16:16 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

19 dic 2025, 16:16 UTC

Charlas de Mercado

U.K. Public Borrowing Data Shows Slow Progress in Reducing Fiscal Deficit -- Market Talk

19 dic 2025, 16:05 UTC

Adquisiciones, fusiones, absorciones

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dic 2025, 16:04 UTC

Adquisiciones, fusiones, absorciones

Trump Media Is Making a Big Pivot. Kodak Tried That, Too. -- Barrons.com

19 dic 2025, 15:37 UTC

Charlas de Mercado

U.S. Labor Market Weakness Could Cause Further Fed Rate Cuts -- Market Talk

19 dic 2025, 15:21 UTC

Charlas de Mercado

West-Coast Liquor Store Strike Weighed on Canada Retail Data -- Market Talk

19 dic 2025, 15:09 UTC

Charlas de Mercado

Gold Flat But Set for Weekly Gains -- Market Talk

19 dic 2025, 15:09 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Syndax Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

85.36% repunte

Estimación a 12 meses

Media 38.5 USD 85.36%

Máximo 56 USD

Mínimo 27 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Syndax Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

Comprar

Mantener

Vender

De acuerdo con 11 analistas que ofrecen calificaciones bursátiles a para Syndax Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

9.91 / 14.15Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimiento

By Acuity

348 / 374 Clasificación en Salud

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.